Authorized purpose: aPROMISE X accepts, stores, displays, manipulates, quantifies, and reports digital medical images from nuclear-medicine imaging using PSMA PET/CT, with tools for marking regions of interest and quantitative oncology review by healthcare professionals or researchers.
Clinical role
Medical-image processing, measurement, quantification, visualization, and reporting support.
Images and patients
PET/SPECT/Nuclear Medicine · Whole-body oncology anatomy represented in PSMA PET/CT studies
Key limitation
Keep in mind: Use only labeled PSMA PET/CT inputs and supported workflows; marked or quantified outputs require professional review and do not replace clinical judgment.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: aPROMISE X accepts, stores, displays, manipulates, quantifies, and reports digital medical images from nuclear-medicine imaging using PSMA PET/CT, with tools for marking regions of interest and quantitative oncology review by healthcare professionals or researchers.
Which images or clinical context are in scope?Modality: PET/SPECT/Nuclear Medicine Anatomy or clinical context: Whole-body oncology anatomy represented in PSMA PET/CT studies Input: Supported DICOM images, study metadata, and release-specific user inputs.
Who uses it?Intended users: Qualified imaging professionals and physicians trained for the represented anatomy and workflow.
What does the software produce?Output: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.
What is its most important limitation?Key limitation: Use only labeled PSMA PET/CT inputs and supported workflows; marked or quantified outputs require professional review and do not replace clinical judgment.
Clinical takeaway. Clinical role: aPROMISE X accepts, stores, displays, manipulates, quantifies, and reports digital medical images from nuclear-medicine imaging using PSMA PET/CT, with tools for marking regions of interest and quantitative oncology review by healthcare professionals or researchers.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports software verification and validation; a digital phantom study of accuracy, linearity and limit of detection against a NEMA digital reference object, where all SUV and volume quantification tests met predetermined acceptance criteria; a comparison showing equivalent performance to the predicate for marking and quantifying user-defined regions in PSMA PET/CT; and an analytical clinical study showing more reproducible, efficient tracer-uptake quantification than manual while maintaining physicians' diagnostic performance. Clinical studies are stated as not necessary. Results are as reported in the FDA submission, not independent validation.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
aPROMISE X accepts, stores, displays, manipulates, quantifies, and reports digital medical images from nuclear-medicine imaging using PSMA PET/CT, with tools for marking regions of interest and quantitative oncology review by healthcare professionals or researchers.
Use only labeled PSMA PET/CT inputs and supported workflows; marked or quantified outputs require professional review and do not replace clinical judgment.
The exact FDA document reports software verification and validation; a digital phantom study of accuracy, linearity and limit of detection against a NEMA digital reference object, where all SUV and volume quantification tests met predetermined acceptance criteria; a comparison showing equivalent performance to the predicate for marking and quantifying user-defined regions in PSMA PET/CT; and an analytical clinical study showing more reproducible, efficient tracer-uptake quantification than manual while maintaining physicians' diagnostic performance. Clinical studies are stated as not necessary. Results are as reported in the FDA submission, not independent validation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification and validation testing were conducted and documentation was provided as recommended by" … "Digital Phantom Validation Study. This study assessed the accuracy, linearity, and limit of detection of aPROMISE X against the known values of a digital reference object (NEMA phantom). All SUV and volume quantification tests of aPROMISE X met their predetermined acceptance criteria.". Read from the exact FDA decision document on 2026-11-14.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
The exact FDA document reports software verification and validation; a digital phantom study of accuracy, linearity and limit of detection against a NEMA digital reference object, where all SUV and volume quantification tests met predetermined acceptance criteria; a comparison showing equivalent performance to the predicate for marking and quantifying user-defined regions in PSMA PET/CT; and an analytical clinical study showing more reproducible, efficient tracer-uptake quantification than manual while maintaining physicians' diagnostic performance. Clinical studies are stated as not necessary. Results are as reported in the FDA submission, not independent validation.
FDA source
Exact FDA submission
Checked 2026-11-14
Packet wording: "Software verification and validation testing were conducted and documentation was provided as recommended by" … "Digital Phantom Validation Study. This study assessed the accuracy, linearity, and limit of detection of aPROMISE X against the known values of a digital reference object (NEMA phantom). All SUV and volume quantification tests of aPROMISE X met their predetermined acceptance criteria.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
Reported specificity
Not applicable
Not applicable
Not applicable
Checked 2026-09-04
Specificity is not promoted as a product-wide endpoint for this device or software function. Compare only an exact endpoint, threshold, population, version, and source if later verified.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
K220590 FDA evidence package for aPROMISE X
DesignFDA 510(k) substantial-equivalence decision evidence and product verification described in the exact submission.
PopulationWhole-body oncology anatomy represented in PSMA PET/CT studies
Scopeexact submission
Tested versionaPROMISE X configuration described in K220590
IndependenceSponsor or vendor study
K220590
Manufacturer evidence submitted for the exact FDA decision. It is not independent clinical validation, and local technical, clinical, privacy, security, and workflow acceptance remains necessary.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K220590 by exact native submission identifier. This does not exclude product-family, later, or adverse-event information.
Public source
Exact FDA submission
Checked 2026-09-04
Exact-identifier review does not prove absence of all product-family safety signals.
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United States
This is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Supported DICOM images, study metadata, and release-specific user inputs.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The exact FDA package describes DICOM 3 input and DICOM or JPG report output for supported PSMA PET/CT workflows; verify patient matching, routing, and archive behavior locally.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes a cloud web service or local server-network deployment for the aPROMISE X release; verify current hosting, service responsibility, contracts, and site configuration locally.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Unresolved route: Measurements, segmentations, visualizations, calculations, models, and reports for professional review.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes a cloud web service or local server-network deployment for the aPROMISE X release; verify current hosting, service responsibility, contracts, and site configuration locally.
Exact FDA submission
Checked 2026-09-04
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, and site configuration remain separate evidence.
The exact FDA package describes DICOM 3 input and DICOM or JPG report output for supported PSMA PET/CT workflows; verify patient matching, routing, and archive behavior locally.
Exact FDA submission
Checked 2026-09-04
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, and archive behavior still require acceptance testing.
Only qualified imaging professionals and physicians trained for the represented anatomy and workflow should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
Monitor K220590 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only labeled PSMA PET/CT inputs and supported workflows; marked or quantified outputs require professional review and do not replace clinical judgment.
Exact FDA submission
Checked 2026-09-04
Monitoring guidance is buyer-facing implementation guidance derived from the exact cleared scope; it is not a claim that the FDA package provides a live monitoring service.
The exact FDA package describes a cloud web service or local server-network deployment for the aPROMISE X release; verify current hosting, service responsibility, contracts, and site configuration locally.
exact submission · checked 2026-09-04
FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The exact FDA package describes DICOM 3 input and DICOM or JPG report output for supported PSMA PET/CT workflows; verify patient matching, routing, and archive behavior locally.
exact submission · checked 2026-09-04
Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use only labeled PSMA PET/CT inputs and supported workflows; marked or quantified outputs require professional review and do not replace clinical judgment.
exact submission · checked 2026-09-04
Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04
No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K220590 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use only labeled PSMA PET/CT inputs and supported workflows; marked or quantified outputs require professional review and do not replace clinical judgment.
exact submission · checked 2026-09-04
Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. medical-image processing and analysis software limits remain submission-specific.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Human reviewedStatus
2026-09-20Last searched
27Fields reviewed
12Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission
No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not publicly available - checked 2026-09-04 - Exact FDA submission
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
Authorized purpose: syngo.via MI Workflows, Scenium, and syngo MBF provide PET, SPECT, nuclear-medicine, CT, and MR viewing, manipulation, quantification, longitudinal comparison, and analysis for oncology, cardiology, neurology, organ function, and selected radiation-planning support.
Authorized purpose: Opulus Lymphoma Precision segments and visualizes lesions and measures total metabolic tumor volume in whole-body FDG-PET/CT for patients already diagnosed with FDG-avid lymphoma; trained physicians can accept/reject annotated output, but radiologist review makes the final interpretation and the device is not a screening/diagnostic substitute.
Authorized purpose: uMI Panorama combines PET and CT to provide quantitative radiopharmaceutical distribution, diagnostic anatomical and attenuation information, and fused PET/CT images for qualified healthcare professionals supporting detection, localization, diagnosis, staging, restaging, treatment planning, and treatment-response evaluation across oncology, cardiology, neurology, and other disorders; its CT subsystem can also perform standalone diagnostic imaging and protocol-governed low-dose lung cancer screening.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.